199 related articles for article (PubMed ID: 35837793)
1. Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment.
Mercuri E; Baranello G; Boespflug-Tanguy O; De Waele L; Goemans N; Kirschner J; Masson R; Mazzone ES; Pechmann A; Pera MC; Vuillerot C; Bader-Weder S; Gerber M; Gorni K; Hoffart J; Kletzl H; Martin C; McIver T; Scalco RS; Yeung WY; Servais L;
Eur J Neurol; 2023 Jul; 30(7):1945-1956. PubMed ID: 35837793
[TBL] [Abstract][Full Text] [Related]
2. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.
Poirier A; Weetall M; Heinig K; Bucheli F; Schoenlein K; Alsenz J; Bassett S; Ullah M; Senn C; Ratni H; Naryshkin N; Paushkin S; Mueller L
Pharmacol Res Perspect; 2018 Dec; 6(6):e00447. PubMed ID: 30519476
[TBL] [Abstract][Full Text] [Related]
3. [Risdiplam for the treatment of spinal muscular atrophy].
Vlodavets DV
Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.
Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Servais L; Xiong H; Zanoteli E; Baranello G; Bruno C; Day JW; Deconinck N; Klein A; Mercuri E; Vlodavets D; Wang Y; Dodman A; El-Khairi M; Gorni K; Jaber B; Kletzl H; Gaki E; Fontoura P; Darras BT;
Lancet Neurol; 2022 Dec; 21(12):1110-1119. PubMed ID: 36244364
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
Mercuri E; Deconinck N; Mazzone ES; Nascimento A; Oskoui M; Saito K; Vuillerot C; Baranello G; Boespflug-Tanguy O; Goemans N; Kirschner J; Kostera-Pruszczyk A; Servais L; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Staunton H; Yeung WY; Martin C; Fontoura P; Day JW;
Lancet Neurol; 2022 Jan; 21(1):42-52. PubMed ID: 34942136
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
Sturm S; Günther A; Jaber B; Jordan P; Al Kotbi N; Parkar N; Cleary Y; Frances N; Bergauer T; Heinig K; Kletzl H; Marquet A; Ratni H; Poirier A; Müller L; Czech C; Khwaja O
Br J Clin Pharmacol; 2019 Jan; 85(1):181-193. PubMed ID: 30302786
[TBL] [Abstract][Full Text] [Related]
7. Risdiplam in Type 1 Spinal Muscular Atrophy.
Baranello G; Darras BT; Day JW; Deconinck N; Klein A; Masson R; Mercuri E; Rose K; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Seabrook T; Fontoura P; Servais L;
N Engl J Med; 2021 Mar; 384(10):915-923. PubMed ID: 33626251
[TBL] [Abstract][Full Text] [Related]
8. Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).
Markati T; Fisher G; Ramdas S; Servais L
Expert Opin Investig Drugs; 2022 May; 31(5):451-461. PubMed ID: 35316106
[TBL] [Abstract][Full Text] [Related]
9. Risdiplam: A Review in Spinal Muscular Atrophy.
Paik J
CNS Drugs; 2022 Apr; 36(4):401-410. PubMed ID: 35284988
[TBL] [Abstract][Full Text] [Related]
10. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).
Oskoui M; Day JW; Deconinck N; Mazzone ES; Nascimento A; Saito K; Vuillerot C; Baranello G; Goemans N; Kirschner J; Kostera-Pruszczyk A; Servais L; Papp G; Gorni K; Kletzl H; Martin C; McIver T; Scalco RS; Staunton H; Yeung WY; Fontoura P; Mercuri E;
J Neurol; 2023 May; 270(5):2531-2546. PubMed ID: 36735057
[TBL] [Abstract][Full Text] [Related]
11. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
Darras BT; Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Xiong H; Zanoteli E; Baranello G; Bruno C; Vlodavets D; Wang Y; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Fontoura P; Servais L;
N Engl J Med; 2021 Jul; 385(5):427-435. PubMed ID: 34320287
[TBL] [Abstract][Full Text] [Related]
12. Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain.
Cornell N; Childs AM; Wraige E; Munot P; Ambegaonkar G; Chow G; Hughes I; Illingworth M; Majumdar A; Marini-Bettolo C; Parasuraman D; Spinty S; Willis T; Scoto M; Baranello G;
J Neuromuscul Dis; 2024; 11(2):361-368. PubMed ID: 38189761
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).
Ratni H; Ebeling M; Baird J; Bendels S; Bylund J; Chen KS; Denk N; Feng Z; Green L; Guerard M; Jablonski P; Jacobsen B; Khwaja O; Kletzl H; Ko CP; Kustermann S; Marquet A; Metzger F; Mueller B; Naryshkin NA; Paushkin SV; Pinard E; Poirier A; Reutlinger M; Weetall M; Zeller A; Zhao X; Mueller L
J Med Chem; 2018 Aug; 61(15):6501-6517. PubMed ID: 30044619
[TBL] [Abstract][Full Text] [Related]
14. Risdiplam: First Approval.
Dhillon S
Drugs; 2020 Nov; 80(17):1853-1858. PubMed ID: 33044711
[TBL] [Abstract][Full Text] [Related]
15. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy.
Sergott RC; Amorelli GM; Baranello G; Barreau E; Beres S; Kane S; Mercuri E; Orazi L; SantaMaria M; Tremolada G; Santarsiero D; Waskowska A; Yashiro S; Denk N; Fürst-Recktenwald S; Gerber M; Gorni K; Jaber B; Jacobsen B; Mueller L; Nave S; Scalco RS; Marzoli SB;
Ann Clin Transl Neurol; 2021 Jan; 8(1):54-65. PubMed ID: 33231373
[TBL] [Abstract][Full Text] [Related]
16. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
Kletzl H; Marquet A; Günther A; Tang W; Heuberger J; Groeneveld GJ; Birkhoff W; Mercuri E; Lochmüller H; Wood C; Fischer D; Gerlach I; Heinig K; Bugawan T; Dziadek S; Kinch R; Czech C; Khwaja O
Neuromuscul Disord; 2019 Jan; 29(1):21-29. PubMed ID: 30553700
[TBL] [Abstract][Full Text] [Related]
17. Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy.
Cleary Y; Gertz M; Grimsey P; Günther A; Heinig K; Ogungbenro K; Aarons L; Galetin A; Kletzl H
Clin Pharmacol Ther; 2021 Dec; 110(6):1547-1557. PubMed ID: 34347881
[TBL] [Abstract][Full Text] [Related]
18. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy.
Ando S; Suzuki S; Okubo S; Ohuchi K; Takahashi K; Nakamura S; Shimazawa M; Fuji K; Hara H
Sci Rep; 2020 Oct; 10(1):17472. PubMed ID: 33060681
[TBL] [Abstract][Full Text] [Related]
20. Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims Analysis.
Pineda ED; To TM; Dickendesher TL; Shapouri S; Iannaccone ST
Adv Ther; 2024 Jun; 41(6):2446-2459. PubMed ID: 38709394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
